Michelle Brown
Vice President, Portfolio Development, Oncology Moderna
Seminars
• Streamlining mRNA manufacturing workflows to reduce IVT, LNP, Purification cycle time, and manual intervention
• Optimizing Phase II manufacturing operations to support a smooth transition to latestage readiness with improved repeatability, regulatory alignment, and trial scalability
• Operationalizing real-time analytics, digital batch release, and platform-based regulatory strategies across end-to-end manufacturing
• Translating lessons from V940 to inform indication expansion and optimize antigen design across tumor types with differing immune responsiveness
• Validating evolving antigen strategies in early-stage settings to accelerate clinical translation and enable faster access
• Navigating regulatory considerations to determine when antigen selection strategy constitutes a new product vs an extension of platform intent
• Integrating tumor profiling, neoantigen prediction, and manufacturing timelines to enable rapid patient-specific vaccine deployment
• Designing robust clinical trials to inform pivotal strategy: from patient selection to combination approaches
